PharmaPoint: Psoriasis - China Drug Forecast and Market Analysis to 2022

USA - English

• USA - English

London (PRWEB) September 16, 2013 -- PharmaPoint: Psoriasis - China Drug Forecast and Market Analysis to 2022

Summary

GlobalData has released its new Country report, “PharmaPoint: Psoriasis - China Drug Forecast and Market Analysis to 2022”. There are no long-term effective therapies for Psoriasis (PsO), so this remains at the top of the list for unmet needs. While physicians agree that biologics are relatively safe and effective, these therapies are still lacking because of their immunosuppressant nature and lack of understanding as to their exact mechanism of action.

GlobalData does not expect pipeline products to launch in China during the forecast period due to loyalty to the few brands that are prescribed and trust in its domestic biosimilars. By forecast end, Enbrel will still be behind Remicade, as it will experience positive growth and total sales, compared with Remicade growth and sales. As previously mentioned, the biosimilars - specifically, infliximab - will actually lead all biologic sales and patient shares.

Scope

• Overview of Psoriasis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
• Detailed information on the key drugs in the China including product description, safety and efficacy profiles as well as a SWOT analysis.
• Sales forecast for the top drugs in China from 2012 to 2022.
• Analysis of the impact of key events as well the drivers and restraints affecting the China Psoriasis market.

Reasons to buy

• Understand and capitalize by identifying products that are most likely to ensure a robust return
• Stay ahead of the competition by understanding the changing competitive landscape for Psoriasis
• Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
• Make more informed business decisions from insightful and in-depth analysis of drug performance
• Obtain sales forecast for drugs from 2012 to 2022 in China.

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 9
3 Disease Overview 12
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology 14
3.2 Symptoms 17
4 Disease Management 18
4.1 Treatment Overview 19
4.2 China 23
4.2.1 Diagnosis 23
4.2.2 Clinical Practice 23
5 Competitive Assessment 25
5.1 Overview 25
5.2 Strategic Competitor Assessment 26
5.3 Product Profiles – Major Brands 27
5.3.1 Enbrel (etanercept) 27
5.3.2 Remicade (infliximab) 32
5.3.3 Taclonex (calcipotriene hydrate and betamethasone dipropionate) 38
5.3.4 Methotrexate Sodium (numerous generic names) 42
5.3.5 Minor Therapeutic Drug Classes Used in Psoriasis 46
5.3.6 Non-Pharmacological Therapy 47
6 Opportunity and Unmet Need 49
6.1 Overview 49
6.2 Unmet Needs 50
6.2.1 Improved Drug Safety and Efficacy Profiles 50
6.2.2 Biomarkers for Predicting Remission 51
6.2.3 More Cost-Effective Therapies Through Oral Formulation and Biosimilars 51
6.2.4 Education and Treatment of Psychological Factors Accompanying Psoriasis 52
6.2.5 An Effective Biologic/Systemic Topical Therapy 52
6.2.6 More Effective Treatment for Mild Psoriasis, Specifically UV Therapies 53
6.2.7 Physician Education About the Different Types of Psoriasis, not Just Plaque Psoriasis 53
6.3 Opportunities 54
6.4 Unmet Needs Gap Analysis 54
6.4.1 Predictive Tools for Diagnosis and Treatment 55
6.4.2 Target Specificity 55
6.4.3 Topical Biologic/Systemic Therapeutic Options 56
6.4.4 Helping Patients with Psychological Issues Associated with Psoriasis 56
7 Pipeline Assessment 57
7.1 Overview 57
7.2 Promising Drugs in Clinical Development 58
7.2.1 Phase II Pipeline Products 60
7.2.2 Phase I Pipeline Products 62
7.2.3 Biosimilars Pipeline Products 63
8 Market Outlook 66
8.1 China 66
8.1.1 Forecast 66
8.1.2 Key Events 69
8.1.3 Drivers and Barriers 69
9 Appendix 71
9.1 Bibliography 71
9.2 Abbreviations 78
9.3 Methodology 82
9.4 Forecasting Methodology 82
9.4.1 Diagnosed Psoriasis Patients 82
9.4.2 Percent Drug-Treated Patients 83
9.4.3 Drugs Included in Each Therapeutic Class 83
9.4.4 General Pricing Assumptions 84
9.4.5 Individual Drug Assumptions 85
9.4.6 Generic Erosion 87
9.5 Physicians and Specialists Included in this Study 88
9.6 Primary Research – Prescriber Survey 89
9.7 About the Authors 90
9.7.1 Analysts 90
9.7.2 Global Head of Healthcare 91
9.8 About GlobalData 92
9.9 Disclaimer 92

1.1 List of Tables

Table 1: Immune Cells Involved in Lesions 14
Table 2: Symptoms of Psoriasis 17
Table 3: Minimal Investigative Measures Required Before Prescribing Biologics for Psoriasis 20
Table 4: Treatment Guidelines for Psoriasis 22
Table 5: Top Three Biologics Prescribed for Moderate to Severe Psoriasis by Market, 2012 22
Table 6: Leading Treatments for Psoriasis, 2013 26
Table 7: Product Profile – Enbrel 28
Table 8: Enbrel SWOT Analysis, 2013 31
Table 9: Product Profile – Remicade 33
Table 10: Efficacy Results of RESTORE1 Trial of Remicade vs. MTX at Week 26 34
Table 11: Safety Results (AEs) of RESTORE1 Trial of Remicade vs. MTX at Week 16 35
Table 12: Remicade SWOT Analysis, 2013 37
Table 13: Product Profile – Taclonex 39
Table 14: Taclonex SWOT Analysis, 2013 41
Table 15: Product Profile – Methotrexate 43
Table 16: Methotrexate SWOT Analysis, 2013 45
Table 17: Summary of Minor Therapeutic Drug Classes for Psoriasis, 2013 46
Table 18: Overall Unmet Needs in Psoriasis – Current Level of Attainment 50
Table 19: Clinical Unmet Needs in Psoriasis – Gap Analysis, 2013 55
Table 20: Psoriasis – Phase Pipeline, 2013 58
Table 21: Comparison of Therapeutic Classes in Development for Psoriasis, 2013 59
Table 22: Phase II Psoriasis Pipeline, 2013 60
Table 23: Phase I Psoriasis Pipeline, 2013 62
Table 24: Biosimilars Pipeline, 2013 65
Table 25: Sales Forecasts ($) for Psoriasis in China, 2012–2022 67
Table 26: Key Events Impacting Sales for Psoriasis in China 2012–2022 69
Table 27: Psoriasis Market in China – Drivers and Barriers, 2012–2022 69
Table 28: Physicians Surveyed, By Country 89

1.2 List of Figures

Figure 1: Psoriatic Plaque on Elbow of Patient 13
Figure 2: The Three Layers of the Skin and Associated Structures 15
Figure 3: Healthy Skin Versus Psoriatic Skin 16
Figure 4: BB-UVB Therapy Guidelines, According to the AAD 48
Figure 5: NB-UVB Therapy Guidelines, According to the AAD 48
Figure 6: Competitive Assessment of Late-Stage Pipeline Agents in Psoriasis, 2012–2022 58
Figure 7: Estimated Sales of Biosimilars vs. Their Branded Counterparts in Psoriasis, 2012–2022 64
Figure 8: Sales for Psoriasis in China by Drug Class, 2012-2022 68

Read the full report:

PharmaPoint: Psoriasis - China Drug Forecast and Market Analysis to 2022

http://www.reportbuyer.com/pharma_healthcare/therapeutic/pharmapoint_psoriasis_china_drug_forecast_market_analysis_2022_1.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: [email protected]
Tel: +44 208 816 85 48
Website: http://www.reportbuyer.com

Sarah Smith, Research Advisor at Reportbuyer.com, +44 208 816 85 48, [email protected]